| Literature DB >> 32133365 |
Ovidiu Samoila1, Diana Gocan1.
Abstract
Total bilateral limbal stem cell deficiency results from various pathologies, from burns (either chemical or physical) to Sjogren Syndrome, aniridia or ocular cicatricial pemphigoid. After the loss of stem cells, normal corneal epithelium is replaced by a more opaque and vascularized conjunctival epithelium, causing loss of vision. After 1997, cultivation techniques for limbal stem cells became possible. In parallel, cultivation techniques for oral mucosa epithelial cells were also available. The aim of our review was to summarize the clinical outcomes following allogenic cultured limbal stem cell transplant (allogenic CLET), and on the other hand, oral mucosa derived epithelium transplant (cultivated oral mucosa epithelial transplant-COMET or cultivated autologous oral mucosal epithelial cell sheet-CAOMECS), in the case of total bilateral limbal stem cell loss. Thirty studies matching the inclusion criteria were found. The clinical improvement in both methods was reported similar, with percentages higher than 50% of the treated cases. However, the comparison between studies was difficult to achieve due to the lack of a universal and objective grading tool for assessing post-operative results. The definition of clinical improvement was problematic, because success was defined differently, depending on the study. Moreover, some of the studies followed both autologous and allogenic CLET, but described the results together, for both procedures, and therefore it was impossible to analyze them separately. COMET presented some advantages compared to CLET. By using autologous cells, there was no risk of immune activation and no immunosuppression was needed. COMET, however, might be associated with increased risk of persistent epithelial defects and graft failure, compared with allogenic CLET.Entities:
Keywords: allogenic; cornea; cultivation techniques; limbal transplant; oral mucosa; stem cells
Year: 2020 PMID: 32133365 PMCID: PMC7040221 DOI: 10.3389/fmed.2020.00043
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
The size of limbal and oral mucosa biopsies in allogenic CLET and COMET/CAOMECS studies.
| Daya et al. ( | 1–2 mm | |
| Shimazaki et al. ( | Not mentioned | |
| Kawashima et al. ( | 1 × 3 mm | |
| Shortt et al. ( | 2–3 mm | |
| Pauklin et al. ( | 1 × 2 mm | |
| Basu et al. ( | 2 × 2 mm | |
| Prabhasawat et al. ( | 2 × 2/3 × 1 mm | |
| Qi et al. ( | Not mentioned | |
| Shortt et al. ( | Not mentioned | |
| Zakaria et al. ( | Not mentioned | |
| Ramírez et al. ( | 2 × 2 mm | |
| Ganger et al. ( | 2 × 2 mm | |
| Parihar et al. ( | 2 × 2 mm | |
| Chen et al. ( | Not mentioned | |
| Cheng et al. ( | Not mentioned | |
| Behaegel et al. ( | 1 × 2 mm | |
| Borderie et al. ( | 1 mm | |
| Campbell et al. ( | Not mentioned | |
| Wang et al. ( | Not mentioned | |
| Nishida et al. ( | 3 × 3 mm | |
| Chen et al. ( | 6 × 6 mm | |
| Nakamura et al. ( | Not mentioned | |
| Satake et al. ( | 8 mm punch | |
| Priya et al. ( | 4 × 2 mm | |
| Burillon et al. ( | 3 × 3 mm | |
| Sotozono et al. ( | 6 mm | |
| Kolli et al. ( | 3 mm | |
| Kocaba ( | 3 × 3 mm | |
| Dobrowolski et al. ( | 3–5 mm2 | |
| Kim et al. ( | 0.8 × 1.5 – 1 × 2 cm2 | |
| Wang et al. ( | 4 × 4 mm |
Results following CLET and COMET.
| Daya et al. ( | SjS, burns, other | 4 | 12–50 months | NA (improvement of visual acuity and transparency) | Counting fingers to 20/25 | 0 | |
| Shimazaki et al. ( | SjS, burns, other | 20 | 6–85 months | 70%; Improvement of BCVA, 40%; | >20/2,000 | 10 primary epithelial failure | |
| Kawashima et al. ( | Burns, SjS | 4 | 25.1 months | 41.7–62.5%; | Improvement 2 lines, after PK | 1 PED | |
| Shortt et al. ( | Burns, aniridia, other | 7 | 13 months | 71% | Light perception to 20/125 | 1 infectious keratitis | |
| Pauklin et al. ( | Burns | 14 | 9–73 months | 50%, re-saturation of ocular surface integrity | >20/500 | NA | |
| Basu et al. ( | Burns, SjS, OCP, other | 21 | 12–120 months | 71.4% | 20/200–20/40 | 25% PED and stromal melting | |
| Prabhasawat et al. ( | Burns, SjS, other | 7 | 6–47 months | 85.7% | Hand movement to 20/40 | 1 infectious keratitis | |
| Qi et al. ( | Burns | 41 | 12–24 months | NA | Not mentioned | 10 rejections | |
| Shortt et al. ( | Aniridia, SjS | 17 | 36 months | Improvement of BCVA−79% at 6 months, | Improvement, 2 lines | NA | |
| Zakaria et al. ( | Burns, aniridia | 3 | 25–48 months | 66% | Counting fingers to 20/100 | NA | |
| Ramírez et al. ( | SjS, burns, | 9 | 36 months | 66.7 % | No light perception-20/20 | 0 | |
| Ganger et al. ( | SjS, burns | 8 | 24.7 months | 50 and 37.5% increased BCVA by 1 line | Improvement, 1–2 lines | NA | |
| Parihar et al. ( | Burns, SjS, OCP, allergy | 20 | 12 months | 68% stable surface (Shirmer, BUT, fluorescein staining); | Improvement, 2 lines | 1 perforation | |
| Chen et al. ( | Burns, trauma, SJS | 41 | 10–89 months | 32/41 (78.04%) | 20/400 (PK, LPK) | NA | |
| Cheng et al. ( | Burns | 80 | 12–60 months | 50% | >20/400 | 18.8% PED | |
| Behaegel et al. ( | Aniridia, burns, microftalmia | 4 | 25 months | 1/4 total success; | Counting fingers to 20/50 | NA | |
| Borderie et al. ( | Burns, aniridia, surgeries | 7 | 66–101 months | 29% (3 years); 0% (5 years) | Decreased BCVA, by 0.7 lines | 40 adverse reactions | |
| Campbell et al. ( | Burns, aniridia, OCP | 13 | 18 months | 5/8 increased VA | Improvement, up to 20/20 | NA | |
| Wang et al. ( | Burns | 41 | 23.3 months | 71,4% | Improvement, 2 lines | 3 PED, 4 rejections | |
| Nishida et al. ( | SjS, OCP | 4 | 13–15 months | NA (improvement of visual acuity and transparency) | 20/300–20/25 | 0 | |
| Chen et al. ( | Burns | 4 | 27–35 months | NA (persistence of cells) | 20/400–20/40 | NA | |
| Nakamura et al. ( | Burns, OCP, other | 17 | 55 months | ↑ VA 53% at 36 months | Hand movement to 20/40 | PED 5–26% | |
| Satake et al. ( | SjS, burns, OCP | 36 | 6–54.9 months | stable surface 64.8% at 1 year, 53.1% at 3 years | 0–20/30; | 22,5% PED | |
| Priya et al. ( | Burns, SJS | 7 | 1–34 months | 3/7 (42%) anatomical; from which 2 with visual improvement (28%) | Light perception to 20/200 | 2 rejections | |
| Burillon et al. ( | Burns, aniridia, other | 26 | 12 months | 75% (16 patients) | Hand movement to 020/50 | 1 perforation | |
| Sotozono et al. ( | Burns, SjS, OCP, other | 40 | 6.2–85.6 months | Improved BCVA: 50%—SJS, 42,9%—OCP, 20%—burns | Improvement, at least | 40% PED, 5% stromal melting, 5% slight-mod infection | |
| Kolli et al. ( | Burns | 2 | 21–41 months | NA (stable epithelium) | 20/200–20/63 | NA | |
| Kocaba ( | Burns, aniridia, other | 23 | 28 months | Improved BCVA 74% | Improvement, 2.3 lines | 1 perforation 1 rejection | |
| Dobrowolski et al. ( | Aniridia | 13 | 12–18 months | 76.4% stable surface; | Hand movement−20/200 | 3 graft failures | |
| Kim et al. ( | Burns, SjS | 8 | 2–15 months | 75% | Improvement > 2 lines | 50% PED | |
| Wang et al. ( | Burns | 32 | 16.1 months | 52.9% | Decreased -improvement 2 lines | 9 PED, 5 stromal melting |
CAOMECS.
Complications post-PK: 2 endothelial rejections (months 18–24).
Complications post-PK: 69.2% graft failure, 33.3% endothelial rejection, 11.1% traumatic dehiscence, 22.2% recurrence of LSCD.
Complications post-PK: 1 perforation, 1 endothelial rejection.
SjS, Sjogren Syndrome; OCP, ocular cicatricial pemphigoid; PED, persistent epithelial defect; NA, not available; BCVA, best corrected visual acuity.
Rosacea blepharoconjunctivitis, ectodermal dysplasia.
OCP, keratoconjunctivitis, unknown cause.
Ectodermal dysplasia, Reiger's anomaly.
Allergy, contact lens hypoxia.
Allergy, dry eye syndrome, multiple eye surgeries.
Squamous cell carcinoma, graft vs. host disease.
Contact lens hypoxia, Lyell syndrome, rosacea keratitis, neuroparalytic keratitis, Groenow dystrophy, trachoma, hepatitis C, cystinosis.
Graft vs. host disease, Salzmanns degeneration, radiation keratopathy, drug induced LSCD, idiopathic LSCD.
Contact lens hypoxia, Lyell syndrome, rosacea keratitis, neuroparalytic keratitis, Groenow dystrophy, trachoma, hepatitis C, cystinosis.
Figure 1Distribution of clinical studies from 2004 to 2019; comparison between CLET and COMET/CAOMECS.